Takara Bio: Clinical Development of "Cancer Immunotherapy" jointly performed with CI&H, Chinese Academy of Medical Sciences
Takara Bio Inc. agreed on August 31, 2004 to undertake clinical development of cancer immunotherapy intended for commercialization jointly with Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing.
Presently, in China, too, malignant tumor is the leading cause of death, same as in Japan (reported by Ministry of Health, People's Republic of China). Under such conditions, Clinical trial will be carried out at CIH for autologous activated lymphocyte therapy with remarkably few adverse reactions, the fourth cancer therapy following surgical therapy, chemotherapy, and radiotherapy, as well as autologous activated lymphocyte therapy using RetroNectin®.
By the end of 2004, the cell processing facilities will be inaugurated in CIH. Application for the clinical trial of cancer immunotherapy will be submitted in 2005. In early 2006, the clinical trial of cancer immunotherapy by CIH will be started in 100 patients who have undergone surgical operations for cancer. These activities will be conducted by Takara Bio in cooperation with Takara Biomedical Technology Beijing Co. Ltd., its subsidiary company. In the future, the clinical trial results will be linked to development of gene immunotherapy which combines immunotherapy with gene therapy.
CIH is the leading cancer therapy facilities in China and is one of the WHO collaboration centers for cancer research, and is one of the sites for drug clinical trial of State Food and Drug Administration, China. The Hospital has 12 clinical departments and 11 auxiliary departments, and has an annual inpatient load of about 10,000 and outpatient of about 240,000.
Takara Bio has developed wide range of patented gene-transduction technologies including RetroNectin® process and original technologies for effectively proliferating immunocytes, which are essential for implementing the cell & gene therapy against cancers. In collaboration with CIH, Takara Bio hopes to accelerate its clinical developments of cell & gene therapy in China.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
